教育经历

2000.06-2003.05    英国伦敦大学, 病毒免疫学博士

1987.09-1990.06    中国科学院武汉病毒研究所, 病毒学硕士

1983.09-1987.06    湖南师范大学, 生物学学士

工作经历

2009.01-至今          中国科学院武汉病毒研究所，研究员

2000.06-2008.12    St George's, University of London, UK, Research Fellow; Senior Lecturer

2000.03-2000.05    中国科学院武汉病毒研究所，副研究员

1997.03-2000.02    University of Louisville, USA, Research Associate

1990.07-1997.02    中国科学院武汉病毒研究所，研究实习员；助理研究员

研究内容

人免疫缺陷病毒1型（HIV-1）和人单纯疱疹病毒2型（HSV-2）均可通过黏膜性传播，能够引发持续性感染，且存在协同感染风险，目前无疫苗和治愈性药物。学科组聚集具有重要临床意义和防治挑战的黏膜传播病毒，特别是HIV-1和HSV-2，从病毒在黏膜上的感染机制、免疫应答以及生物阻断等方面开展研究，致力于研发黏膜疫苗和清除潜伏病毒等新型抗病毒策略，并将相关共性技术推广至其他高致病性黏膜传播病毒的防控。

主持项目

先后主持及承担国家自然科学基金、英中合作、国家重点基础研究发展计划、国家传染病防控科技重大专项、国家重点研发计划、转化和合作研发等项目或课题多项。

成果（*通讯作者）

HIV-1 and HSV-2 related:

1. Ni F, Hu K, Li M, Yang M, Xiao Y, Fu M, Zhu Z, Liu Y*, Hu Q*. Tat-dependent conditionally replicating adenoviruses expressing diphtheria toxin A for specifically killing HIV-1 infected cells. Mol Ther. 2024, 32(7):2316-2327. (Patent pending)

2. Li C, Zhang M, Guan X, Hu H, Fu M, Liu Y*, Hu Q*. HSV-2 glycoprotein D inhibits NF-kappa B activation by interacting with p65. J Immunol. 2021, 206 (12) 2852-2861.

3. Zhang M, Fu, Li M, Hu H, Gong S*, Hu Q*. HSV-2 inhibits type-I interferon signaling mediated by a novel E3 ubiquitin-protein ligase activity of viral protein ICP22. J Immunol. 2020, 205(5): 1281-1292.

4. Fu M, Hu K, Hu H, Ni F, Du T, Shattock RJ, Hu Q*. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion. Vaccine. 2019, 37(51):7501-7508.

5. Yan Y, Hu K, Deng X, Guang X, Luo S, Tong L, Du T, Fu M, Zhang M, Liu Y, Hu Q*. Immunization with CCL19-HSV-2 gB fusion constructs protects mice against lethal vaginal challenge. J Immunol. 2015, 195(1):329-338. (Patented)

6. Li C, Guan X, Du T, Jin W, Wu B, Liu Y, Wang P, Hu B, Griffin G, Shattock R, Hu Q*. Inhibition of HIV-1 infection of primary CD4⁺ T cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol. 2015, 96(8): 2381-2393. (Highly cited; Patented)

7. Zhang M, Liu Y, Wang P, Guan X, He S, Luo S, Li C, Hu K, Jin W, Du T, Yan Y, Zheng Z, Zheng Z, Wang H, Hu Q*. HSV-2 immediate-early protein US1 inhibits IFN-β production by suppressing association of IRF-3 with IFN-β promoter. J Immunol. 2015, 194(7): 3102-3115.

8. Hu K, Luo S, Tong L, Huang X, Jing W, Huang W, Du T, Yan Y, He S, Griffin G, Shattock R, Hu Q*. CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue. J Immunol. 2013,191:1935-1947. (Cover article)

9. Du T, Hu K, Yang J, Jing J, Li C, Stieh D, Griffin G, Shattock R, Hu Q*. Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination. Antimicrob Agents Chemother. 2012, 56(9):4640-4649. (Patented)

10. Huang W, Hu K, Luo S, Zhang M, Li C, Jin W, Liu Y, Griffin G, Shattock R, Hu Q*. HSV-2 infection of humane epithelial cells induces CXCL9 expression and CD4⁺ T cell migration via activation of p38-C/EBP-β pathway. J Immunol. 2012, 188(12):6247-6257. (Recommended by F1000 Medicine)